Skye Bioscience (SKYE) EBIT Margin (2013 - 2014)
Skye Bioscience's (SKYE) quarterly EBIT Margin came in at 10.84% in Q2 2014, down 1416.0% year-over-year from 0.82% in Q2 2013, and down 83.94% quarter-over-quarter from 5.89% in Q4 2013.
Powered by 
Analysis
Skye Bioscience (SKYE) EBIT Margin (2013 - 2014) Analysis & Trends
Skye Bioscience (SKYE) has reported EBIT Margin for 2 consecutive years, with 10.84% the latest figure, recorded in Q2 2014.
- On a quarterly basis, EBIT Margin fell 1416.0% year-over-year to 10.84% in Q2 2014; TTM through Apr 2014 was 32.77%, a N/A change from a year earlier, with the FY2013 full-year figure at 1.11%, down 2646.0% from the prior year.
- EBIT Margin was 10.84% for Q2 2014 at Skye Bioscience, down from 5.89% in the prior quarter.
- Over five years, EBIT Margin peaked at 3.32% in Q2 2013 and troughed at 10.84% in Q1 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -25,380.93% |
| 10 | Skye Bioscience | 11.01 Mn | 11.01 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2014 | -10.84% |
| Oct 31, 2013 | -5.89% |
| Jul 31, 2013 | 0.82% |
| Apr 30, 2013 | 3.32% |
| Jan 31, 2013 | -10.84% |